530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Stradella, A., Johnson, M., Goel, S., Chandana, S.R., Galsky, M.D., Calvo, E., Moreno, V., Park, H., Arkenau, T., Cervantes, A., Fariñas-Madrid, L., Mileshkin, L., Fu, S., Plummer, R., Evans, J., HorVolume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.644
Date:
September, 2020
File:
PDF, 118 KB
2020
File converter
More search results
More benefits 
